Page 4 - பளபளப்பு ஆயுட்காலம் லிமிடெட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(2) Glow LifeTech has the exclusive rights for MyCell Technology in the United States, Canada and Mexico for one of the primary ingredients used in ArtemiC, a COVID-19 Treatment Candidate with successful Phase II Clinical Results The formulation statistically significantly improved the clinical recovery of COVID-19 patients in the treatment group in comparison with placebo and 100% of the patients in the treatment group fully recovered within 15 days Positive results from a phase II double blind randomized controlled clinical trial show the MyCell Technology ArtemiC formulation, successfully met the primary and secondary endpoints for safety and efficacy 1 ArtemiC is a natural anti-inflammatory formulation by Glow partner Swiss PharmaCan and MGC Pharma, intended to suppress cytokine storm and clinical deterioration prevention to support the recovery of COVID-19 patients

United statesW clark kentClark kentBernhard langerRelay medical corpGlow mycell technologyGlow lifetech ltdPharmaceuticals ltdMycell technology artemiSwiss pharmacan ag micelle technologyMycell technologyMicelle technologyPlacebo groupCanadian securities exchangeAteba resources incGlow lifetech